Welcome to our dedicated page for Beam Therapeutics SEC filings (Ticker: BEAM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Beam Therapeutics Inc. (BEAM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biotechnology issuer. Beam files reports and current reports with the U.S. Securities and Exchange Commission that describe its financial condition, clinical development progress and material corporate events related to its precision genetic medicines platform.
Investors can review Form 8-K filings in which Beam reports items such as quarterly financial results and significant transactions. For example, the company has used Form 8-K to furnish press releases announcing results for quarters ended June 30 and September 30, and to disclose an Agreement and Plan of Merger under which it acquired an early-stage life sciences company in exchange for upfront shares and potential milestone-based consideration.
In addition to 8-Ks, Beam’s periodic reports on Form 10-K and Form 10-Q (accessible via EDGAR and summarized on this page when available) typically include information on its base editing platform, programs such as risto-cel (formerly BEAM-101), BEAM-302 and BEAM-301, risk factors, liquidity and capital resources. These filings also describe regulatory designations, clinical trial status and collaboration arrangements that are important for understanding the company’s development-stage business.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify disclosures on topics like clinical milestones, cash runway, collaboration agreements and equity issuances. Real-time updates from EDGAR ensure that new Beam filings, including any future Forms 4 reporting insider transactions or proxy statements on executive compensation and governance, are surfaced promptly.
By combining official SEC documents with AI-generated overviews, this page helps investors and researchers analyze Beam’s regulatory history, financial reporting and material events that influence the BEAM stock narrative.
Beam Therapeutics CEO John M. Evans reported multiple equity transactions in Beam Therapeutics Inc. stock. He exercised stock options for 50,000 shares of common stock at an exercise price of $0.67 per share, then sold 50,000 shares in open-market transactions at weighted average prices of $22.3692 and $22.7634 per share.
The sales were made under a Rule 10b5-1 trading plan adopted on May 16, 2025. Evans also received 90,000 restricted stock units under the Beam 2019 Equity Incentive Plan, vesting in four equal annual installments, and now holds 986,667 shares directly and 103,000 shares indirectly through a trust.
BEAM affiliate submitted a Form 144 notice proposing the sale of 20,000 shares of Common Stock. The filing lists the disposition method as Restricted Stock Vesting with an issuer-related transfer dated 03/31/2026. Recent reported sales by the same holder include $33,978.85 for 1,254 shares on 01/02/2026, $644,830.68 for 18,629 shares on 01/15/2026, and $46,614 for 1,371 shares on 01/22/2026. The cover records 101,856,245 shares (as of 04/02/2026).
BEAM reported an insider sale notice on Form 144 for proposed sales of Common Stock by an affiliate. The excerpt shows a restricted stock vesting event of 26,250 shares dated 03/31/2026 and a listed sale by Giuseppe Ciaramella of 35,000 shares for $1,120,041.49.
ETRADE Financial Corporation reported Rule 144 activity involving Common Stock. The filing shows two open-market sales by John M. Evans of 25,000 shares on 01/29/2026 for $734,582.50 and 25,000 shares on 01/30/2026 for $708,946.63. The notice also lists 66,874 shares tied to Restricted Stock Vesting with an effective date of 03/31/2026 described as for services rendered.
BEAM affiliate submitted a Form 144 notice to sell 25,000 shares of Common Stock by stock option exercise on 03/31/2026. The filing lists the sale method as cash and identifies the broker as Morgan Stanley Smith Barney LLC. The excerpt also shows three prior reported sales by the same holder in the past three months: 25,000 shares on 03/30/2026, 25,000 on 01/30/2026, and 25,000 on 01/29/2026, with the dollar amounts shown alongside each sale.
The issuer filed a Rule 144 notice showing a stock option exercise and proposed sale of 25,000 shares of Common stock, dated 03/30/2026. The filing lists two prior sales by John M. Evans on 01/29/2026 and 01/30/2026, each for 25,000 shares at cash amounts shown.
The Vanguard Group filed an amended Schedule 13G/A reporting no beneficial ownership in Beam Therapeutics common stock. The filing states 03/13/2026 and includes a disclosure that Vanguard reorganized on January 12, 2026, after which certain subsidiaries report holdings separately. The amendment is signed on 03/26/2026 and lists 0% ownership and 0 shares beneficially owned.
Beam Therapeutics Inc. terminated its 2019 cross-license agreement with Bio Palette Co., Ltd. as of March 2, 2026, in connection with Bio Palette’s planned dissolution. That agreement had given Beam exclusive, royalty-bearing rights to certain base editing patents for treating human disease worldwide, excluding microbiome products in Asia, while Beam granted Bio Palette exclusive, royalty-bearing rights to use certain Beam base and gene editing patents in the microbiome field in Asia.
Before this termination, Bio Palette and Kobe University ended their own license, which activated a previously arranged standby license between Beam and Kobe. Under this standby license, Kobe directly provides Beam an exclusive license, of the same scope as the original Bio Palette license, to practice specified patents. All rights and licenses between Beam and Bio Palette have now ended, the parties granted each other a mutual release of claims, and no further payments are owed between Beam and Bio Palette under either the termination agreement or the prior license.
Beam Therapeutics President Giuseppe Ciaramella reported insider transactions involving 35,000 shares on Common Stock. He exercised a stock option for 35,000 shares at $17.00 per share, converting a derivative award into directly held Common Stock.
On the same date, he then sold 35,000 shares of Common Stock at a weighted average price of $32.0012 per share under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2025. Following these transactions, he directly owned 190,216 shares of Common Stock and 397,313 shares underlying stock options.